faded building interior background
faded building interior background
faded building interior background

Challenges of
treating RA

Rheumatoid arthritis (RA) affects 1.6 million people in the United States. If left untreated, RA leads to progressive joint damage, with one in three patients permanently work disabled within 5 years.1,2

An estimated 90% of RA patients in the US are treated with TNF inhibitor (TNFi) therapies as first-line targeted treatments.3 However, a majority of patients fail to achieve adequate response with this approach.4

These low response rates have serious long-term consequences for patients. Those who inadequately respond to TNFi therapies have twice the number of joint replacement surgeries, emergency department visits, and inpatient hospitalizations in their first year of treatment.5

PrismRA patient wearing an orange shirt
male ra patient
male RA patient in orange

Consequences of prescribing ineffective
TNFi therapy

Low response rate, high cost

Despite a low response rate, ~90% of RA patients are prescribed a TNFi as a first-line targeted therapy at a cost of $59,000 per patient/year.6

Decreased response rates after the first-line

Response rates to alternative biologic therapies decline by 27% if taken after first failing a TNFi.7

Disease progression

Failing to treat-to-target and effectively control disease activity increases the likelihood of irreversible joint damage, the need for surgery and chronic pain for
RA patients.5,8,9

Predicting response to rheumatoid arthritis

Until now, doctors have not been able to understand which drug would be most effective for an individual patient. “Step-therapy” treatment approaches may require patients to cycle through two or more TNFi therapies despite the low probability of success10 with each subsequent TNFi.

Valuable time is wasted trying multiple therapies that do not get a patient to disease remission or low disease activity.11

A slow start in finding the optimal treatment for each patient can have long-term consequences; response rates to alternative targeted therapy decline by 27% if taken after failing a TNFi.7

Find out how PrismRA can help you identify patients who are unlikely to respond to TNFi medications so you can prescribe an alternate
therapy sooner.

I was diagnosed with RA many years ago and went through the gamut of all the drugs “that might help” for several years.
Person living with RA